Downregulation of microRNA-497 is associated with upregulation of synuclein γ in patients with osteosarcoma

December 2016
Experimental & Therapeutic Medicine;Dec2016, Vol. 12 Issue 6, p3761
Academic Journal
The present study aimed to investigate the effects of microRNA (miRNA/miR)-497 expression levels on the expression levels of synuclein γ (SNCG) in serum samples, as well as osteosarcoma and lung-metastatic tissue samples, from patients with osteosarcoma. Between December 2010 and August 2013, fasting peripheral blood was collected from 36 patients with osteosarcoma for serum separation. In addition, osteosarcoma and lung metastatic tissues were resected from 15 osteosarcoma patients with lung metastasis by surgery. Bioinformatics was employed to predict the amount miRNA that binds to SNCG. Reverse transcription-quantitative polymerase chain reaction was used to determine the expression levels of SNCG and miR-497, and western blotting was performed to determine protein expression levels. It was observed that SNCG mRNA and protein expression levels were significantly upregulated in osteosarcoma tissues (P<0.01). Additionally, SNCG mRNA (P<0.01) and protein (P<0.05) expression levels were significantly upregulated in the blood of patients with osteosarcoma. SNCG mRNA and protein expression levels were also significantly upregulated in lung metastatic tissues (P<0.01). miR-497 was significantly downregulated in all three samples; therefore downregulation of miR-497 may lead to the occurrence, development and metastasis of osteosarcoma through the upregulation of SNCG mRNA. In summary, the upregulation of SNCG in blood, osteosarcoma tissue and lung metastatic tissue samples is associated with the dowregulation of miR-497, suggesting that miR-497 may be a potential marker and therapeutic target for the treatment of osteosarcoma.


Related Articles

  • Tumor-Suppressing Effects of miR-429 on Human Osteosarcoma. Liu, Xiaozhou; Liu, Yunlai; Wu, Sujia; Shi, Xin; Li, Lihong; Zhao, Jianning; Xu, Haidong // Cell Biochemistry & Biophysics;Sep2014, Vol. 70 Issue 1, p215 

    Osteosarcoma is the most common primary bone tumor. Recent data indicated miRNAs may be involved in the pathogenesis of osteosarcoma, suggesting some novel targets for therapy. It is known that miR-429 is down-regulated and functions as a tumor suppressor by targeting c-myc and PLGG1 in gastric...

  • Osteosarcomatous differentiation in lung metastases from a malignant phyllodes tumour of the breast. Tsubochi, H.; Sato, N.; Kaimori, M.; Imai, T. // Journal of Clinical Pathology;Apr2004, Vol. 57 Issue 4, p432 

    Osteosarcomatous differentiation of a phyllodes tumour in the breast is extremely rare. A 54 year old woman presented with a painless lump in her left breast and a mastectomy was performed. Microscopically, the tumour was diagnosed as a malignant phyllodes tumour, where no osteosarcomatous...

  • In the news: War against cancer. Hutchinson, Ezzie // Nature Reviews Cancer;Aug2002, Vol. 2 Issue 8, p560 

    Reports on the number of deaths from lung and breast cancer in Great Britain over a 30 year period. Link between smoking cessation and the decline in the number of deaths from lung cancer; Factors contributing to the reduction in the number of deaths due to breast cancer.

  • Lobular Carcinoma in Situ and Infiltrating Ductal Carcinoma: Frequent Presence of DCIS as a Precursor Lesion. Maluf, Horacio; Koerner, Frederick // International Journal of Surgical Pathology;Apr2001, Vol. 9 Issue 2, p127 

    Reports the occurrence of infiltrating ductal carcinoma (IDC) in patients with lobular carcinoma in-situ (LCIS). Difference between IDC ans LCIS; Consideration of DCIS as the direct precursor of IDC in patients with LCIS; Absence of heterozygosity at molecular level in both carcinoma.

  • Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. Burbee, David G.; Forgas, Eva; Zöchbauer-Müller, Sabine; Shivakumar, Latha; Kwun Fong; Boning Gao; Randle, Dwight; Kondo, Masashi; Virmani, Arvind; Bader, Scott; Sekido, Yoshitaka; Latif, Farida; Milchgrub, Sara; Toyooka, Shinichi; Gazdar, Adi F.; Lerman, Michael I.; Zabarovsky, Eugene; White, Michael; Minna, John D.; Burbee, D G // JNCI: Journal of the National Cancer Institute;5/2/2001, Vol. 93 Issue 9, p691 

    Background: The recently identified RASSF1 locus is located within a 120-kilobase region of chromosome 3p21.3 that frequently undergoes allele loss in lung and breast cancers. We explored the hypothesis that RASSF1 encodes a tumor suppressor gene for lung and breast...

  • Spoken presentations.  // Journal of Medical Genetics;Sep2002 Supplement, Vol. 39, pS15 

    Discusses the abstract of the research paper entitled 'SLIT2, a human homologue of the Drosophila Slit2 gene has tumor suppressor activity an is frequently inactivated in lung and breast cancers,' by Ashraf Dallol, N.F. da Silva et al and presented during the British Human Genetics Conference...

  • Cancer: Targeting microRNA blocks metastasis. Harrison, Charlotte // Nature Reviews Drug Discovery;Jun2014, Vol. 13 Issue 6, p418 

    The article presents research showing the target on microRNA regulation for breast cancer treatment.

  • Quantitative evaluation of breast density using a dual‐energy technique on a digital breast tomosynthesis system. Lu, Kun‐Mu; Yeh, Da‐Ming; Cao, Bi‐Hui; Lin, Chia‐Yi; Liang, Chih‐Yu; Zhou, Yu‐Bo; Tsai, Chia‐Jung // Journal of Applied Clinical Medical Physics;Jun2019, Vol. 20 Issue 6, p170 

    Purpose: Although breast density is considered a strong risk factor of breast cancer, its quantitative assessment is difficult. To investigate a quantitative method of measuring breast density using dual‐energy mammographic imaging with central digital breast tomosynthesis in physically...

  • Researchers Discover Key Tumor Suppressor Gene, First to Be Clearly Associated With Sporadic Breast Cancer.  // Ascribe Newswire: Medicine;10/7/2002, p4 

    Scientists have discovered a new tumor suppressor gene that is missing or inactive in as many as 60 percent of breast cancers and is also altered in lung cancer. The gene, called DBC2, for deleted in breast cancer, is among the first tumor suppressor genes to be clearly associated with sporadic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics